Neil Kumar - 16 Aug 2025 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role: Chief Executive Officer, Director
Signature: /s/ Laura Woodhead, Attorney-in-Fact
Issuer symbol: BBIO
Transactions as of: 16 Aug 2025
Transactions value $: -$1,686,119
Form type: 4
Filing time: 19 Aug 2025, 19:38:18 UTC
Previous filing: 18 Aug 2025
Next filing: 22 Aug 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Kumar Neil	Chief Executive Officer, Director	C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO	/s/ Laura Woodhead, Attorney-in-Fact	19 Aug 2025	0001742485

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BBIO	Common Stock	Options Exercise		+64,697	+30%		282,101	16 Aug 2025	Direct	F1
transaction	BBIO	Common Stock	Tax liability	-$1,686,118	-32,855	-12%	$51.32	249,246	16 Aug 2025	Direct	F2
holding	BBIO	Common Stock						4,718,447	16 Aug 2025	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.	F3
holding	BBIO	Common Stock						915,686	16 Aug 2025	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BBIO	Restricted Stock Units	Options Exercise	$0	-33,544	-14%	$0	201,264	16 Aug 2025	Common Stock	33,544		Direct	F1, F4
transaction	BBIO	Restricted Stock Units	Options Exercise	$0	-19,599	-9.1%	$0	195,993	16 Aug 2025	Common Stock	19,599		Direct	F1, F5
transaction	BBIO	Restricted Stock Units	Options Exercise	$0	-11,554	-6.7%	$0	161,753	16 Aug 2025	Common Stock	11,554		Direct	F1, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2	Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 64,697 shares of Common Stock underlying the Reporting Person's RSUs.
F3	The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
F4	The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
F5	The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
F6	The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.